title: Early effects of lasonolide a on pancreatic cancer cells.
abstract: Lasonolide A, a novel polyketide-derived macrolide, was previously identified from an extract of the marine sponge Forcepia sp. in an assay for protein kinase C (PKC) inhibitors. Cytotoxicity testing and profiling of lasonolide A in the National Cancer Institute (NCI) 60 cell panel screen revealed that it was potent toward a broad range of cell lines and also suggested a unique mechanism of action. Contrary to expected results, we found lasonolide A to be a strong activator of PKC in Panc-1 pancreatic carcinoma cells. Downstream mitogen-activated protein kinases, ERK 1/2 and p38 were also rapidly phosphorylated in response to lasonolide A, as was Akt. Microscopy studies revealed that lasonolide A induced blebbing and contraction of the cells within minutes of exposure, and the eventual loss of adherence. However, membrane integrity was maintained and the effects were reversible if lasonolide A was washed from the cells after their loss of adherence. Pretreatment of cells with a myosin II inhibitor, blebbistatin, slowed the early onset, but did not prevent the morphological effects of lasonolide A. Cells stained for actin filaments showed some reduction in stress fiber structure after lasonolide A exposure; however, it did not affect the polymerization of purified actin in vitro. Bisindolemaleimide, a PKC inhibitor, and wortmannin, a phosphoinositide 3-kinase; inhibitor, did not reduce lasonolide A-induced contraction or blebbing or the activation of mitogen-activated protein kinases, although Akt phosphorylation was prevented by wortmannin pretreatment. Our results indicate that lasonolide A activates multiple signal transduction pathways and suggest that the origin is upstream of PKC.
authors.affiliation: Harbor Branch Oceanographic Institute at Florida Atlantic University, Center for Marine Biomedical and BiotechnologyResearch, Fort Pierce, Florida 34946, USA.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Isbrucker
authors.forename: Esther A
authors.initials: EA
authors.lastname: Guzmán
authors.forename: Tara P
authors.initials: TP
authors.lastname: Pitts
authors.forename: Amy E
authors.initials: AE
authors.lastname: Wright
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D015153:Blotting, Western; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects / Q000648:ultrastructure; D002470:Cell Survival / Q000187:drug effects; D003599:Cytoskeleton / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D018942:Macrolides / Q000494:pharmacology*; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010766:Phosphorylation; D011161:Porifera / Q000737:chemistry; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D013778:Tetrazolium Salts; D013844:Thiazoles; D014404:Tubulin / Q000378:metabolism
chemical_list: D000199:Actins; D018942:Macrolides; D047428:Protein Kinase Inhibitors; D013778:Tetrazolium Salts; D013844:Thiazoles; D014404:Tubulin; C450700:lasonolide A; D007770:L-Lactate Dehydrogenase; D011493:Protein Kinase C; D020928:Mitogen-Activated Protein Kinases; C022616:thiazolyl blue
references.citation: J Cell Sci. 1993 Aug;105 ( Pt 4):883-90
references.pmid: 8227210
references.citation: FASEB J. 2004 Mar;18(3):592-4
references.pmid: 14734633
references.citation: J Antibiot (Tokyo). 1991 Jan;44(1):93-102
references.pmid: 2001987
references.citation: J Nat Prod. 2004 Aug;67(8):1351-5
references.pmid: 15332854
references.citation: Methods Enzymol. 1982;85 Pt B:182-210
references.pmid: 6889668
references.citation: Nat Rev Cancer. 2006 Oct;6(10):813-23
references.pmid: 16990858
references.citation: Cell Signal. 2006 Mar;18(3):276-84
references.pmid: 16109477
references.citation: Biochim Biophys Acta. 2002 Apr 3;1589(2):93-103
references.pmid: 12007785
references.citation: Cell Mol Life Sci. 2006 Sep;63(18):2119-34
references.pmid: 16909206
references.citation: Microsc Res Tech. 1999 Oct 1;47(1):18-37
references.pmid: 10506759
references.citation: Cell Mol Life Sci. 2008 Nov;65(22):3525-44
references.pmid: 18668205
references.citation: Science. 2003 Mar 14;299(5613):1743-7
references.pmid: 12637748
references.citation: Angew Chem Int Ed Engl. 2003 Oct 13;42(39):4779-82
references.pmid: 14562347
references.citation: Biochem Pharmacol. 2003 Jul 1;66(1):75-82
references.pmid: 12818367
references.citation: J Biol Chem. 2004 Aug 20;279(34):35557-63
references.pmid: 15205456
references.citation: J Cell Physiol. 2007 Dec;213(3):589-602
references.pmid: 17786953
references.citation: Cancer Res. 1988 Feb 1;48(3):589-601
references.pmid: 3335022
references.citation: Pancreas. 2004 Apr;28(3):353-8
references.pmid: 15084985
references.citation: J Muscle Res Cell Motil. 2004;25(4-5):337-41
references.pmid: 15548862
references.citation: J Antibiot (Tokyo). 1988 Jul;41(7):925-31
references.pmid: 3138226
references.citation: Org Lett. 2006 Feb 2;8(3):475-8
references.pmid: 16435863
references.citation: Chem Asian J. 2008 Oct 6;3(10):1811-23
references.pmid: 18712746
references.citation: J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92
references.pmid: 2738938
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13851-6
references.pmid: 14612571